Customized managed access programs designed for rare disease therapies, guided by real world experience.
Does your rare disease commercial strategy need Managed Access expertise to guide your expansion planning?
RareiTi- a different kind of managed access company.
previous arrow
next arrow

Our advisory practice offers business advice and recommendations on the suitability, design and business impact of Managed Access programs for patients with rare diseases.

We deliver customized global Managed Access Programs designed to meet complex challenges for patients with a rare disease at the point of care.

RareiTi DATA provides the baseline of our strategic customizable analytics platform to accurately capture real-world patient experiences that measure patient outcomes.

Latest from RareiTi VIEW

Managed Access: A Solution with Benefits for Everyone

Managed access programs – also known as compassionate use, early access, and named-patient programs- have clear benefits for patients and physicians. These programs provide an alternative regulatory pathway to help patients access potentially life-altering drugs when they are ineligible for clinical trials or the drug has not been approved in their home country.   Historically, the…

Read More

Latest Tweets @RareiTi

An experienced senior leadership team

40+ rare disease conditions

50+ biotech and pharma companies

200+ managed access programs

100,000s of patients supported with access to treatment

COVID-19 Response

The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.

Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.

Follow us on:


London  •  Chicago  •  New Jersey

©2021 RareiTi